Deliverables

  1. To identify disease specific phenograms which allow rapid screening of novel rodent disease models and the effects of novel compounds.
  2. To develop novel genetic animal models for disease and identify their behavioral phenogram.
  3. To design and synthesize biologically active compounds for CNS targets.
  4. To provide proof of principle for the concept to use pharma-phenograms as tools for early drug selection in the drug discovery pipeline.
  5. To maximize the use of cellular genetic heterogeneity and their molecular response to classify and identify compounds early in the CNS drug discovery pipeline.
  6. To maximize the use of cellular genetic heterogeneity and their cell physiological response to classify and identify compounds early in the CNS drug discovery pipeline.
  7. To maximize the use of genetic heterogeneity in relevant circuitries and their systems response to classify and identify compounds early in the CNS drug discovery pipeline.
  8. To develop hardware and software tools that will generate new behavioral and physiological endpoints, and that allow in-depth mining of the behavioral data space and cross the various levels of analysis from molecules to behavior.
  9. To provide a proof-of-principle validation in human patients of our advanced pre-clinical and postclinical screening methodology.
  10. To further bridge the collaborations between NeuroBasic-PharmaPhenomics and CNS groups in TI-Pharma.
  11. To expand Amsterdam-Rotterdam exchange master course in neuroscience to Utrecht.